OSTTRA LIMITED

Financial Health Assessment: OSTTRA LIMITED

1. Financial Health Score: Provisional B+

I am assigning OSTTRA LIMITED a Provisional B+. The patient is clearly alive, well-monitored, and supported by a robust corporate immune system. However, a definitive A-grade diagnosis is currently restricted because the detailed quantitative "blood work" (profit & loss figures, balance sheet metrics) has not been provided in this dataset. The structural and compliance indicators point to a healthy, well-maintained subsidiary, but the internal financial vitals require a closer look to confirm total wellness.

2. Key Vital Signs

• Pulse / Corporate Status (Active): The company has a strong, steady heartbeat. It is actively registered and not in liquidation, administration, or receivership. There are no signs of corporate cardiac arrest.
• Immune System / Filing Compliance (Strong): The company’s regulatory immune system is functioning perfectly. Accounts are filed up to 31 December 2025, and the confirmation statement is up to date (05 January 2026), with neither overdue. This indicates no external infections or statutory penalties threatening the business.
• Genetic Lineage / Ownership (Complex but Robust): The DNA of this company is highly complex. The People with Significant Control (PSC) register shows deep entanglement with major global corporate entities, including Markit Group Limited, IHS Markit, KKR & Co. Inc., and NEX Optimisation Limited. This indicates the company is a vital organ within a much larger corporate anatomy, receiving significant parent-company shelter and strategic direction.
• Evolution / Corporate History (Adaptive): The company has successfully evolved through several major corporate "surgeries"—transitioning from SwapsWire UK to SwapsWire, then MarkitServ, and most recently to OSTTRA in November 2025. This shows a history of successful M&A integration and rebranding, rather than defensive restructuring.
• Share Capital (£480): The nominal share capital is incredibly low. In a medical sense, this is like having a very low baseline weight—it is entirely normal for a subsidiary that relies on parent-company funding (the corporate IV drip) rather than its own retained earnings to finance operations.

3. Diagnosis

Based on the available indicators, OSTTRA LIMITED presents as a healthy, well-integrated corporate subsidiary. The recent name change to OSTTRA and the complex PSC structure strongly suggest that this entity is the result of a joint venture or merger (specifically the combination of S&P Global's MarkitServ and CME Group's NEX Optimisation).

The absence of quantitative financials (turnover, net assets, cash position) means we cannot measure the company's internal "cholesterol" (debt levels) or its "metabolism" (cash flow conversion). However, structurally, the business is in excellent shape. The fact that it files full accounts (rather than dormant or micro-accounts) means it is an active trading entity, and its backing by multi-billion-pound global entities (like IHS Markit and KKR) provides a massive safety net against sudden financial illness.

4. Recommendations

To move from a Provisional B+ to a confirmed A-grade bill of health, the following preventative care and diagnostic steps should be taken: * Conduct a Full Blood Panel: Retrieve the last few years of fully filed accounts from Companies House to examine the balance sheet for Net Current Assets and Retained Profits. We need to ensure the company is generating its own healthy cash flow and not entirely reliant on parent-company life support. * Monitor Intercompany Vitals: Given the complex ownership, ensure that intercompany loans and trading balances with Markit Group, IHS Markit, and NEX are properly documented and not creating hidden "blood clots" (unpayable liabilities) on the balance sheet. * Maintain Compliance Hygiene: Continue the excellent track record of timely filings with Companies House. As a high-profile subsidiary, any administrative oversight could trigger unnecessary regulatory fevers.